However, in platinum-resistant or refractory ovarian cancer, clinical trials of PLK1 inhibitors such as volasertib have demonstrated only modest efficacy, with progression-free survival not superior to chemotherapy and frequent hematologic toxicities as the principal dose-limiting events [26, 27]. The gene discussed is PLK1; the disease is ovarian carcinoma.